{"id":4762,"date":"2025-10-10T15:17:22","date_gmt":"2025-10-10T12:17:22","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4762"},"modified":"2025-11-03T20:18:13","modified_gmt":"2025-11-03T17:18:13","slug":"wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332\/","title":{"rendered":"Come\u00e7a o ensaio cl\u00ednico de fase 2 da terapia de salto de \u00e9xon WVE-N531 para distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Wave Life Sciences Ltd. anunciou em seu site ClinicalTrials.gov que um ensaio cl\u00ednico de fase 2 do WVE-N531 (Terapia de salto do exon 53) come\u00e7ar\u00e1 em novembro de 2025 com 175 participantes na Jord\u00e2nia e no Reino Unido.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u00cdndice<\/h2><nav><ul><li><a href=\"#what-is-wve-n-531-exon-skipping-therapy\">O que \u00e9 a terapia de salto de \u00e9xon WVE-N531<\/a><\/li><li><a href=\"#wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">Terapia de salto de \u00e9xon WVE-N531 Fase 2 \u2013 NCT07209332<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">Como participar do ensaio cl\u00ednico WVE-N531<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-wve-n-531-exon-skipping-therapy\">O que \u00e9 a terapia de salto de \u00e9xon WVE-N531<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>WVE-N531 \u00e9 uma terapia experimental de salto de exon que est\u00e1 sendo desenvolvida como uma terapia potencial para pacientes com DMD pass\u00edveis de salto de exon 53.<\/strong> O WVE-N531 foi desenvolvido utilizando as melhores modifica\u00e7\u00f5es qu\u00edmicas de oligonucleot\u00eddeos da Wave, incluindo a qu\u00edmica de estrutura PN. O WVE-N531 recebeu a Designa\u00e7\u00e3o de Medicamento \u00d3rf\u00e3o e a Designa\u00e7\u00e3o de Doen\u00e7a Pedi\u00e1trica Rara da Food &amp; Drug Administration (FDA) dos EUA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ler mais<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/pt\/mutations-and-deletions-amenable-to-exon-53-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Muta\u00e7\u00f5es e dele\u00e7\u00f5es pass\u00edveis de terapias de salto do exon 53 para distrofia muscular de Duchenne<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"847\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg\" alt=\"Muta\u00e7\u00f5es e dele\u00e7\u00f5es pass\u00edveis de terapias de salto do exon 53 para distrofia muscular de Duchenne\" class=\"wp-image-4566\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg 847w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-248x300.jpg 248w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-768x929.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1270x1536.jpg 1270w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1693x2048.jpg 1693w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-10x12.jpg 10w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-347x420.jpg 347w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-150x181.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-300x363.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-696x842.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1068x1292.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1920x2323.jpg 1920w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping.jpg 1984w\" sizes=\"auto, (max-width: 847px) 100vw, 847px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">Terapia de salto de \u00e9xon WVE-N531 Fase 2 \u2013 NCT07209332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este \u00e9 um estudo de extens\u00e3o aberto (OLE) de Fase 2 para avaliar a seguran\u00e7a a longo prazo, tolerabilidade, efic\u00e1cia, farmacocin\u00e9tica e farmacodin\u00e2mica (PD) por meio de potenciais biomarcadores explorat\u00f3rios de WVE-N531 intravenoso (IV) em pacientes com DMD que participaram de outro estudo de WVE-N531.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In\u00edcio do estudo (estimado)<\/strong>: 2025-11<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o prim\u00e1ria (estimada)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o do estudo (estimada)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 175<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tipo de estudo<\/strong>: Intervencionista<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Localiza\u00e7\u00e3o<\/strong>: Jord\u00e2nia, Reino Unido<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Idades eleg\u00edveis para estudo<\/strong>: Crian\u00e7a, Adulto, Adulto mais velho<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principais crit\u00e9rios de inclus\u00e3o e exclus\u00e3o. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07209332\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07209332<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">Como participar do ensaio cl\u00ednico WVE-N531<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Para participar do ensaio cl\u00ednico de fase 2 da terapia de salto de exon WVE-N531, voc\u00ea pode usar as informa\u00e7\u00f5es de contato abaixo. <strong>Saber mais<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/pt\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">Como participar de ensaios cl\u00ednicos para Duchenne (DMD)?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nome<\/strong>: Opera\u00e7\u00f5es Cl\u00ednicas<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de telefone<\/strong>: 855-215-4687<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: clinicaltrials@wavelifesci.com<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ler mais<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensaios cl\u00ednicos para distrofia muscular de Duchenne (lista de todas as pesquisas)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Wave Life Sciences Ltd. announced on its ClinicalTrials.gov website that a phase 2 clinical trial of WVE-N531 (Exon 53 Skipping Therapy) will begin in November 2025 with 175 participants in Jordan and the United Kingdom. What is WVE-N531 Exon Skipping Therapy WVE-N531 is an investigational exon skipping therapy being developed as a potential therapy for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4769,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,155,154,328,422,153,327],"class_list":["post-4762","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-exon-53","tag-exon-53-skipping","tag-exon-53-skipping-therapy","tag-exon-53-treatment","tag-wave-life-sciences","tag-wve-n531"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4762"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4762\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/4769"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=4762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=4762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}